Targeted Agents for Adjuvant Therapy of Colon Cancer

References 

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
   • CrossRef
2. Tabernero J, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol. 2004;23:1092s;(abstr 3512)
3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:399–401
   • MEDLINE
   • CrossRef
4. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–944
   • Abstract
   • CrossRef
5. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, Leucovorin, and Levamisole in high-risk stage II and III colon cancer/ final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8678
   • MEDLINE
   • CrossRef
6. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole, in patients with Dukes’ B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-04. J Clin Oncol. 1999;17:3553–3559
   • MEDLINE
7. O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250
   • MEDLINE
8. André T, Colin P, Louvet C, et al. Semimonthly vs. monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol. 2003;21:2896–2903
   • MEDLINE
   • CrossRef
9. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704
   • CrossRef
10. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc Am Soc Clin Oncol. 2004;23:246;(abstr 3500)
11. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol. 2005;23;:246s;(abstr 3502)
12. van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3). J Clin Oncol. 2005;23:3s;(abstr LBA8)
13. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med. 2004;350:2343–2351
    • CrossRef
14. de Gramont A, Boni C, Navarro J, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005;23:246s;(abstr 3501)
15. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol. 2005;23:16s;(abstr LBA3500)